Skip to content
10-Q

Quarterly Report

Ensysce Biosciences, Inc. ENSC ENSCW

0001641172-25-009955

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 8, 2025 2.37M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $3.05M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $3.5M
Stockholders Equity Q1 2025 · Mar 31, 2025 $3.05M
Stockholders Equity Q1 2025 · Dec 31, 2024 $3.71M
Current Liabilities Q1 2025 · Mar 31, 2025 $1.76M
Current Liabilities Q1 2025 · Dec 31, 2024 $2.21M
Total Liabilities Q1 2025 · Mar 31, 2025 $1.89M
Total Liabilities Q1 2025 · Dec 31, 2024 $2.22M
Current Assets Q1 2025 · Mar 31, 2025 $4.4M
Current Assets Q1 2025 · Dec 31, 2024 $5.34M
Total Assets Q1 2025 · Mar 31, 2025 $4.61M
Total Assets Q1 2025 · Dec 31, 2024 $5.6M
Shares Diluted restated Q1 2025 · Mar 31, 2024 379.63K sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.41M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$8.21
Eps Basic restated Q1 2025 · Mar 31, 2024 −$8.21
Rd Expense Q1 2025 · Mar 31, 2024 $778.9K
Operating Income Q1 2025 · Mar 31, 2024 −$1.84M
Revenue Q1 2025 · Mar 31, 2024 $305.72K